Increased morbidity during long‐term follow‐up of survivors of thrombotic thrombocytopenic purpura
Authors: Shruti Chaturvedi, Hashim Abbas, Keith R. McCrae
Journal: American Journal of Hematology (2015)

Thrombotic thrombocytopenic purpura (TTP) is an uncommon disorder caused by a congenital or acquired deficiency of ADAMTS13, a Von Willebrand factor (VWF) cleaving serine protease. Generally, the focus on treatment of TTP has been on management of acute episodes because these were almost invariably fatal prior to the advent of plasma exchange. With plasma exchange, mortality has decreased from >90% to approximately 15%. The increasing use of corticosteroids and Rituximab with plasma exchange has led to a decrease in the duration of plasma exchange needed to induce remission and, hence, plasma exchange-related complications. Recovery from TTP has generally been considered complete except for a significant risk of relapse, particularly within the first year after diagnosis. However, recent reports have suggested that survivors of TTP have a high incidence of hypertension, renal insufficiency, persistent cognitive deficits, depression, poorer quality of life, and higher-than-expected mortality 1-3. We conducted this retrospective cohort analysis to determine the prevalence of chronic kidney disease (CKD), hypertension, depression, stroke, and other psychiatric and neurologic conditions during long-term follow-up in survivors of TTP. We identified 100 consecutive patients with a clinical diagnosis of TTP of whom 57 had documented ADAMTS13 activity <5%. The latter were included in the study cohort and were followed until death or date of last clinical contact. Clinical and laboratory data as well as information concerning clinical outcomes, including death, relapse, CKD (serum creatinine > 2 mg/dl or greater than 1.5 times baseline persisting for at least 3 months), hypertension (two blood pressure measurements greater than 140/90 mmHg or the initiation of antihypertensive therapy), diabetes mellitus (single hemoglobin A1C value of >6.5%), stroke (new neurologic deficits persisting for > 7 days with a documented cerebrovascular event on brain magnetic resonance imaging), and depression (started on antidepressant medications and a psychiatrist or primary care physician documented a diagnosis of major depression), were extracted from the electronic medical record. A one-way chi-squared test was used to compare period prevalence of the study outcomes with expected rates in the reference United States population obtained from six cycles of the National Health and Nutrition Examination Survey (NHANES) data (2001–2012) adjusted for age and sex. All analyses were performed using SPSS version 20 (IBM Corp., Armonk, NY), and significance was set at a P-value of 0.05. The median patient age was 45 years (range, 16–79 years), and 38 (66.7%) were female. Additional information on patient characteristics is provided in the Supporting Information Table S1. All patients were treated with plasma exchange, and 48 (84%) received concurrent corticosteroids. Patients were followed for a median period of 59 months (range, 10–117 months). Four (7%) patients died during an acute episode of TTP, and 11 (19.3%) suffered relapses. At initial presentation, 10 (19.4%) of the survivors (n = 53) had a preexisting diagnosis of hypertension, 3 (5.6%) had CKD, 4 (7.5%) had major depression, and 4 (7.5%) had a diagnosis of stroke (patients with stroke during the course of an acute TTP episode were included). Over the follow-up period, the number of patients affected by hypertension increased to 20 (39.6%), stroke to 7 (13.2%), CKD to 10 (18.8%), and depression needing pharmacologic treatment to 10 (18.8%). The period prevalence of hypertension (39.6% versus 29.8%, P = 0.044), stroke (13.2% versus 1.81%, P = 0.007), and depression requiring pharmacologic treatment (18.8% versus 6.1, P = 0.016) were significantly higher in TTP survivors compared with an age- and sex-matched reference US population. The prevalence of CKD (18.8% versus 16.8%, P = 0.077) was not significantly higher than that of the reference population. We also noted a significant rate of other mental health disorders, such as anxiety (n = 9), bipolar disorder (n = 1), and conversion disorder (n = 1). Figure 1 shows the rates of these morbidities in TTP survivors compared with the reference population. Prevalence of morbidity outcomes in TTP survivors over a median follow-up of 59 months compared with reference United States population (data from NHANES database). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Other recent studies suggest that TTP survivors are a vulnerable population with higher rates of chronic morbidities such as hypertension, renal insufficiency, depression, systemic lupus, obesity, and overall poor quality of life. In a recent cohort study of 57 survivors of TTP, Deford et al. 1 described higher-than-expected rates of hypertension (40%), major depression (19%), and systemic lupus erythematosus (12%). Similar to our findings, other investigators have reported higher rates of depression and psychiatric illnesses as well as increased rates of fatigue and problems with concentration and memory 2, 3. There are several possible explanations for these findings. First, microvascular ischemia during acute episodes of TTP may cause persistent organ damage. Second, although the course of ADAMTS13 activity after recovery from TTP is poorly understood, persistently low activity may play a role in microvascular thrombosis by increasing levels of ultra-large VWF multimers and enhanced platelet aggregation. Lower ADAMTS13 activity has been documented in patients with ischemic cerebrovascular accidents, myocardial infarction, and hypertensive crises 4, 5 The high prevalence of depression and psychiatric morbidities may, in part, be attributable to the psychological effects and sequelae of a life-threatening illness, a phenomenon that is well documented in intensive care unit survivors 6. In conclusion, we demonstrate that survivors of TTP have high rates of chronic morbidities, such as hypertension, depression, stroke, and chronic renal disease, which limit the quality of life, and ultimately survival. This highlights the need for continued follow-up to address these negative health consequences in a timely manner. Further studies into the pathogenesis of these outcomes, including the role of ADAMTS13 and VWF, are warranted. The authors recognize the contributions of the clinicians who cared for these patients. Shruti Chaturvedi1, Hashim Abbas2, Keith R. McCrae3,4* 1Division of Hematology and Oncology, Vanderbilt University, Nashville, Tennessee; 2Internal Medicine, Cleveland Clinic, Cleveland, Ohio; 3Department of Hematology and Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio; 4Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, Ohio Additional Supporting Information may be found in the online version of this article. Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.